IN2014DN11205A - - Google Patents
Info
- Publication number
- IN2014DN11205A IN2014DN11205A IN11205DEN2014A IN2014DN11205A IN 2014DN11205 A IN2014DN11205 A IN 2014DN11205A IN 11205DEN2014 A IN11205DEN2014 A IN 11205DEN2014A IN 2014DN11205 A IN2014DN11205 A IN 2014DN11205A
- Authority
- IN
- India
- Prior art keywords
- compounds
- relates
- formulae
- iii
- cell lymphoma
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 201000005787 hematologic cancer Diseases 0.000 abstract 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662084P | 2012-06-20 | 2012-06-20 | |
| PCT/US2013/046826 WO2013192423A2 (en) | 2012-06-20 | 2013-06-20 | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN11205A true IN2014DN11205A (enEXAMPLES) | 2015-10-02 |
Family
ID=49769702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN11205DEN2014 IN2014DN11205A (enEXAMPLES) | 2012-06-20 | 2013-06-20 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20150150869A1 (enEXAMPLES) |
| EP (1) | EP2863920B1 (enEXAMPLES) |
| IN (1) | IN2014DN11205A (enEXAMPLES) |
| WO (1) | WO2013192423A2 (enEXAMPLES) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2863920B1 (en) | 2012-06-20 | 2023-03-22 | Eutropics Pharmaceuticals, Inc. | Quinoline derivatives for use in the tratment of breast cancer |
| EP2922544B1 (en) * | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| EP3137079A1 (en) * | 2014-04-28 | 2017-03-08 | The J. David Gladstone Institutes | Inhibitors of jmjd2c as anticancer agents |
| BR112017022666A8 (pt) | 2015-04-20 | 2022-10-18 | Tolero Pharmaceuticals Inc | Preparando resposta à alvocidib por perfilamento mitocondrial |
| HK1251941B (en) | 2015-05-18 | 2020-04-09 | Sumitomo Pharma Oncology, Inc. | Alvocidib prodrugs having increased bioavailability |
| WO2017024073A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JP6619519B2 (ja) | 2016-12-19 | 2019-12-11 | トレロ ファーマシューティカルズ， インコーポレイテッド | プロファイリングペプチドおよび感受性プロファイリングのための方法 |
| WO2018222473A1 (en) * | 2017-06-01 | 2018-12-06 | Albert Einstein College Of Medicine, Inc. | Bax activators and uses thereof in cancer therapy |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| CA3119807A1 (en) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置 |
| WO2023020534A1 (en) * | 2021-08-18 | 2023-02-23 | Nanjing Immunophage Biotech Co., Ltd | Compounds and their uses as mif inhibitors |
| JP2025510646A (ja) | 2022-03-14 | 2025-04-15 | スラップ ファーマシューティカルズ エルエルシー | 多環式化合物 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642903A (en) | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
| US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
| US5578322A (en) | 1990-11-30 | 1996-11-26 | Yamanouchi Pharmaceutical Co., Ltd. | Quick release coated preparation |
| US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| US5380473A (en) | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
| CA2166891C (en) | 1993-07-09 | 2001-07-03 | Sang K. Wong | Method for making freeze dried drug dosage forms |
| US5622852A (en) | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
| US5616344A (en) | 1994-06-14 | 1997-04-01 | Fuisz Technologies Ltd. | Apparatus and process for strengthening low density compression dosage units and product therefrom |
| US5895664A (en) | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
| US5622719A (en) | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
| GB9422836D0 (en) | 1994-11-11 | 1995-01-04 | Wainscoat James | Monitoring malignant disease |
| US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
| WO1998009643A1 (en) | 1996-09-09 | 1998-03-12 | Washington University | Modulation of apoptosis by serine phosphorylation of blc-xl/blc-2 associated cell death regulator |
| US5955593A (en) | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
| US5856445A (en) | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
| US5981201A (en) | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
| CA2281473C (en) | 1997-02-20 | 2007-01-16 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US7064193B1 (en) | 1997-09-17 | 2006-06-20 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
| WO1999016787A1 (en) | 1997-09-26 | 1999-04-08 | Washington University | Cell death agonists |
| US6277406B1 (en) | 1997-10-08 | 2001-08-21 | Fuisz Technologies Ltd. | Easily processed tablet compositions |
| US6165732A (en) | 1997-10-14 | 2000-12-26 | Washington University | Method for identifying apoptosis modulating compounds |
| US7026456B1 (en) | 1998-01-23 | 2006-04-11 | Hoffman-La Roche, Inc. | Antibodies against human IL-12 |
| CA2329868A1 (en) | 1998-05-18 | 1999-11-25 | Apoptosis Technology, Inc. | Compounds, screening methods, and uses involving anti-apoptotic genes and gene products |
| AU5233799A (en) | 1998-08-19 | 2000-03-14 | Washington University | Modulation of apoptosis with bid |
| US6326354B1 (en) | 1998-08-19 | 2001-12-04 | Washington University | Modulation of apoptosis with bid |
| AU2001271426A1 (en) | 2000-07-17 | 2002-01-30 | Washington University | Modulation of apoptosis |
| CN1493159A (zh) | 2000-12-28 | 2004-04-28 | ��ķɭ��ɹ�˾ | 作为诊断辅助的屏上显示 |
| US20020177692A1 (en) | 2001-04-16 | 2002-11-28 | Myriad Genetics, Incorporated | BCL-XL-interacting protein and use thereof |
| EP1436406A4 (en) | 2001-09-24 | 2004-10-13 | Blood Ct Res Foundation | METHOD FOR MODULATING OR EXAMINING THE KU70 MIRROR IN CELLS |
| WO2003057158A2 (en) | 2001-12-31 | 2003-07-17 | Dana-Farber Cancer Institute, Inc. | Method of treating apoptosis and compositions thereof |
| JP2006516383A (ja) | 2002-09-09 | 2006-07-06 | デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｈ３ペプチドおよびその使用方法 |
| ES2254044T3 (es) | 2002-12-26 | 2010-12-30 | ZAKRYTOE AKTSIONERNOE OBSCHESTVO " EVROGEN" | Proteinas fluorescentes procedentes de especies de copepodos y procedimientos para usarlas. |
| WO2004066958A2 (en) | 2003-01-30 | 2004-08-12 | The Trustees Of Princeton University | Caspase-9:bir3 domain of xiap complexes and methods of use |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| EP1601357A4 (en) | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
| US7755765B2 (en) | 2003-03-17 | 2010-07-13 | Massachusetts Institute Of Technology | Method and apparatus for inertial sensing via measurement of trapped orbit dynamics |
| JP2006523314A (ja) | 2003-04-01 | 2006-10-12 | モノグラム バイオサイエンシズ，インコーポレーテッド | バイオマーカーとしてのＥｒｂＢ表面受容体複合体 |
| FR2855650B1 (fr) | 2003-05-30 | 2006-03-03 | Soitec Silicon On Insulator | Substrats pour systemes contraints et procede de croissance cristalline sur un tel substrat |
| CN1302004C (zh) | 2003-08-22 | 2007-02-28 | 浙江海正药业股份有限公司 | 一种阿糖胞苷的制备方法 |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| CA2544223C (en) | 2003-11-05 | 2017-03-07 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| GB0326964D0 (en) | 2003-11-19 | 2003-12-24 | Glaxo Group Ltd | Chemical compounds |
| WO2005100606A2 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| JP2009532033A (ja) | 2006-03-31 | 2009-09-10 | ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド | 細胞の化学感受性を定量する方法 |
| US9360473B2 (en) | 2006-08-16 | 2016-06-07 | Eutropics Pharmaceuticals, Inc. | Assay system to identify therapeutic agents |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| HRP20161562T2 (hr) | 2007-06-29 | 2017-04-21 | Pfizer Inc. | Derivati benzimidazola |
| US20090030005A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
| EP2649997B1 (en) | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| EP3284828A1 (en) | 2008-05-07 | 2018-02-21 | Eutropics Pharmaceuticals, Inc. | Antibodies specific to heterodimers of bcl-2 family and uses thereof |
| US20100015058A1 (en) | 2008-06-25 | 2010-01-21 | Stanford University | Radiolabeled bbn-rgd heterodimers for cancer targeting |
| ES2641471T3 (es) * | 2008-10-06 | 2017-11-10 | The Johns Hopkins University | Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos |
| MX2011008488A (es) | 2009-02-11 | 2011-10-24 | Abbott Lab | Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2. |
| AR075858A1 (es) | 2009-03-18 | 2011-05-04 | Schering Corp | Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa |
| WO2010114922A1 (en) | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| JP5718319B2 (ja) | 2009-05-14 | 2015-05-13 | ネステク ソシエテ アノニム | Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー |
| CN102596935B (zh) * | 2009-06-12 | 2015-02-18 | Abivax公司 | 用于治疗过早衰老和尤其是早衰的化合物 |
| JP2013502399A (ja) | 2009-08-20 | 2013-01-24 | ヴィフォール （インターナショナル） アクチェンゲゼルシャフト | 新規なキノリン系ヘプシジン拮抗薬 |
| MX2012007872A (es) * | 2010-01-06 | 2012-10-03 | Joseph P Errico | Metodos y composiciones de desarrollo de farmacos dirigidos. |
| US20130011393A1 (en) | 2010-01-12 | 2013-01-10 | Johnathan Mark Lancaster | Bad pathway gene signature |
| CA2787784A1 (en) | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| US8785490B2 (en) * | 2010-04-09 | 2014-07-22 | University Of Louisville Research Foundation, Inc. | Compounds for treating disease, for administering, and for pharmaceutical compositions |
| WO2012012653A1 (en) * | 2010-07-21 | 2012-01-26 | Errico Joseph P | Combination therapy with mdm2 and efgr inhibitors |
| US8716295B2 (en) | 2010-10-27 | 2014-05-06 | Yves Pommier | Fluoroquinolone derivatives or sulfonamide moiety-containing compounds as inhibitors of tyrosyl-dnaphosphodiesterase (TDP1) |
| EP2684167B1 (en) | 2011-03-08 | 2020-09-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| EP2863920B1 (en) | 2012-06-20 | 2023-03-22 | Eutropics Pharmaceuticals, Inc. | Quinoline derivatives for use in the tratment of breast cancer |
| CN104736156A (zh) | 2012-06-20 | 2015-06-24 | 范德比尔特大学 | 作为mglur5受体变构调节剂的取代的双环烷氧基吡唑类似物 |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
-
2013
- 2013-06-20 EP EP13806664.2A patent/EP2863920B1/en active Active
- 2013-06-20 US US14/409,789 patent/US20150150869A1/en not_active Abandoned
- 2013-06-20 WO PCT/US2013/046826 patent/WO2013192423A2/en active Application Filing
- 2013-06-20 US US14/410,399 patent/US20150133450A1/en active Pending
- 2013-06-20 IN IN11205DEN2014 patent/IN2014DN11205A/en unknown
-
2018
- 2018-04-02 US US15/943,112 patent/US10765673B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20150133450A1 (en) | 2015-05-14 |
| US20150150869A1 (en) | 2015-06-04 |
| EP2863920B1 (en) | 2023-03-22 |
| EP2863920A2 (en) | 2015-04-29 |
| US10765673B2 (en) | 2020-09-08 |
| US20180221366A1 (en) | 2018-08-09 |
| EP2863920A4 (en) | 2016-07-13 |
| WO2013192423A3 (en) | 2015-06-25 |
| WO2013192423A2 (en) | 2013-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN11205A (enEXAMPLES) | ||
| WO2012122370A3 (en) | Compositions and methods useful for treating diseases | |
| EA201390756A1 (ru) | Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний | |
| MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
| CL2015001771A1 (es) | Inhibidores de histona desmetilasa | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| IN2012DN00471A (enEXAMPLES) | ||
| MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
| MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
| NZ726671A (en) | Compounds useful as inhibitors of atr kinase and combination therapies thereof | |
| EA201590262A1 (ru) | Комбинированное лечение меланомы, включающее введение кобиметиниба и вемурафениба | |
| MX2014010713A (es) | Activacion de procaspasa 3 mediante terapia de combinacion. | |
| MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
| MX2013015340A (es) | Composiciones y metodos para el tratamiento de cancer. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| IL207310A0 (en) | Vaccine compositions | |
| NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| MX336022B (es) | Activadores de pkm2 bicíclicos. | |
| NZ603952A (en) | Phosphaplatins and their use for treatment of cancers | |
| MX2019011469A (es) | Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl). | |
| MX2015001551A (es) | Compuestos y composiciones activadoras de enzima. | |
| MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
| MX359209B (es) | Terapia de combinacion de procaspasa para gliobastoma. |